×
+ All Categories
Log in
English
Français
Español
Deutsch
Report -
Dossier zur Nutzenbewertung gemäß § 35a SGB V · Dokumentvorlage, Version vom 18.04.2013 Bristol-Myers Squibb GmbH & Co.KGaA Nivolumab (Opdivo®) Modul 3 G Plattenepithelkarzinom
Name
Email
Select
Select
Pornographic
Defamatory
Illegal/Unlawful
Spam
Other Terms Of Service Violation
File a copyright complaint
Message
Please pass captcha verification before submit form